Lesson plan
DPAI
DPAI, also known as 4-(N,N-dipropylaminoethyl)indole (4-DPAEI), 2-desoxo-2-ene-ropinirole, or BD-179, is a dopamine receptor agonist and partial ergoline closely related to the clinically used dopamine receptor agonist and antiparkinsonian agent ropinirole. It has a delayed onset of effects and weak actions in vitro, suggestive that it may be a metabolically activated prodrug via 6-hydroxylation into its metabolite 6-HO-DPAI (TL-350). The drug is said to be a highly selective agonist of presynaptic dopamine autoreceptors, with little or no activity at postsynaptic dopamine receptors. It dramatically reduces dopamine release in the caudate nucleus, produces hypolocomotion, and strongly suppresses prolactin secretion in rodents. No effects of DPAI on serotonin receptors have been reported, at least as of 1982. DPAI was first described in the scientific literature by 1980. It was developed independently by David E. Nichols and colleagues and by another group of researchers. Analogues of DPAI in which its propyl groups have been replaced with other alkyl groups such as methyl or ethyl groups, for instance DMAI (BD-214; UCD0076), have also been studied.
Article summary
DPAI, also known as 4-(N,N-dipropylaminoethyl)indole (4-DPAEI), 2-desoxo-2-ene-ropinirole, or BD-179, is a dopamine receptor agonist and partial ergoline closely related to the clinically used dopamine receptor agonist and antiparkinsonian agent ropinirole. It has a delayed onset of effects and weak actions in vitro, suggestive that it may be a metabolically activated prodrug via 6-hydroxylation into its metabolite 6-HO-DPAI (TL-350). The drug is said to be a highly selective agonist of presynaptic dopamine autoreceptors, with little or no activity at postsynaptic dopamine receptors. It dramatically reduces dopamine release in the caudate nucleus, produces hypolocomotion, and strongly suppresses prolactin secretion in rodents. No effects of DPAI on serotonin receptors have been reported, at least as of 1982. DPAI was first described in the scientific literature by 1980. It was developed independently by David E. Nichols and colleagues and by another group of researchers. Analogues of DPAI in which its propyl groups have been replaced with other alkyl groups such as methyl or ethyl groups, for instance DMAI (BD-214; UCD0076), have also been studied.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.